RITONAVIR by Cipla is 12. Approved for combination with other antiretroviral agents for the treatment of hiv-1 infection (). First approved in 2022.
Drug data last refreshed Yesterday
12.1 Mechanism of Action Ritonavir is an antiretroviral drug [see ] . 12.2 Pharmacodynamics Cardiac Electrophysiology QTcF interval was evaluated in a randomized, placebo and active (moxifloxacin 400 mg once-daily) controlled crossover study in 45 healthy adults, with 10 measurements over 12 hours…
Worked on RITONAVIR at Cipla? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Comparing Standard-Dose Versus Adjusted-Dose Lopinavir/Ritonavir Therapy in HIV-Infected Persons With Drug Resistance
Safety of Saquinavir and High Doses of Lopinavir/Ritonavir in Children With HIV
Safety of AMD070 When Administered Alone or Boosted With Low-Dose Ritonavir in HIV Uninfected Men
Safety, Tolerability, and Blood Levels of Ritonavir-Boosted Atazanavir and Rifampin When Taken Together in HIV Uninfected Adults
A Study of Ritonavir (ABT-538) When Used With Nelfinavir in HIV-Infected Patients